Diet quality among children

JAMA Pediatrics

2024-07-08

(Press-News.org) About The Study: Although total dietary quality scores among U.S. children improved overall during 2005-2020, the increase remained suboptimal: lower than 5 points, a significant threshold for children in this analysis of changes in diet quality.

Corresponding Author: To contact the corresponding author, Yongjun Zhang, Ph.D., M.D., email zhangyongjun@sjtu.edu.cn.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamapediatrics.2024.1880)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.1880?guestAccessKey=bb7f97e8-8982-49c8-81c3-62e82491fd54&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070824

END

ELSE PRESS RELEASES FROM THIS DATE:

Acceptability of hospital-at-home care and capacity for caregiver burden

2024-07-08

About The Study: Survey respondents reported substantial acceptability of hospital-at-home care, which did not vary across sociodemographics, health insurance coverage, health status, prior hospitalizations, or telehealth use. Approximately half of respondents agreed that hospital-at-home care was effective, safe, and convenient. Most indicated capacity to perform many caregiver tasks. Corresponding Author: To contact the corresponding author, Melissa A. Frasco, Ph.D., email mfrasco@usc.edu. To access the embargoed ...

Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity

2024-07-08

About The Study: In this population of adults with overweight or obesity, use of tirzepatide was associated with significantly greater weight loss than semaglutide. Future study is needed to understand differences in other important outcomes. Corresponding Author: To contact the corresponding author, Nicholas L. Stucky, M.D., email nicholass@truveta.com. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamainternmed.2024.2525) Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest ...

AJPH study shows that permit to purchase laws are a promising avenue to reduce suicides in young adults

2024-07-08

In 2020, suicide ranked as the third leading cause of death for adults aged 18 to 20 years in the United States. Firearms were implicated in approximately half of these cases, and by 2017, they had surpassed motor vehicles as the leading cause of death in this age group. While ongoing debates on gun violence and mental health have increased public support for restricted firearm access, not much is known about the impact of gun control policies on young adults. To fill this knowledge gap, a recent study published in the August issue of the American Journal of Public Health on July 03, ...

Companies that mitigate climate change reduce their cost of capital

2024-07-08

Fukuoka, Japan —The climate crisis is hitting home with more frequent extreme weather events. Companies, particularly those in high-emission industries, are major contributors to global carbon emissions, therefore making them key players in the fight against climate change. Recognizing this responsibility, many businesses are now taking proactive measures to reduce their carbon footprint, by reducing carbon emissions and transparently sharing their environmental strategies and data. The Task Force on Climate-Related Financial Disclosures ...

Case Western Reserve University receives $1.5M grant from Foundation Fighting Blindness to test possible new treatment for inherited retinal disease

2024-07-08

CLEVELAND—There’s only one U.S. Food and Drug Administration-approved therapy for an inherited retinal disease, and dozens of retinitis pigmentosa (RP) genes for which no therapy is available. With a new three-year, $1.5 million grant from the Foundation Fighting Blindness, Shigemi Matsuyama, an associate professor of ophthalmology and visual sciences at the Case Western Reserve University School of Medicine, will test a possible breakthrough drug that can be taken by mouth—one that may address many RP disease manifestations, regardless of the underlying genetic mutation. “We believe it can serve as the basis of an oral medicine to prevent blindness in RP ...

How to stop cancer cachexia? Start at the top

2024-07-08

Cancer is insidious. Throughout tumor progression, the disease hijacks otherwise healthy biological processes—like the body’s immune response—to grow and spread. When tumors elevate levels of an immune system molecule called Interleukin-6 (IL-6), it can cause severe brain dysfunction. In about 50%-80% of cancer patients, this leads to a lethal wasting disease called cachexia. “It’s a very severe syndrome,” says Cold Spring Harbor Laboratory (CSHL) Professor Bo Li. “Most people with cancer die of cachexia instead of cancer. And once the patient enters this stage, there’s ...

Pulsed field ablation procedures found safe and effective for atrial fibrillation patients

2024-07-08

Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF), according to the largest study of its kind on this new technology, led by the Icahn School of Medicine at Mount Sinai. The “MANIFEST-17K” international study is the first to show important safety outcomes in a large patient population, including no significant risk of esophageal damage, with PFA. PFA is the latest ablation modality approved by the Food and Drug Administration that can be used to restore a regular heartbeat. The findings, published July 8 in Nature Medicine, could lead to more frequent use of PFA instead of conventional therapies to manage AF patients. “MANIEFST-17K ...

Why some abusive bosses get a pass from their employees

2024-07-08

COLUMBUS, Ohio – Why do employees sometimes accept working for an abusive boss? A new study suggests that when a leader is seen as a high performer, employees are more likely to label abuse as just “tough love.” Results showed that workers were less likely to show hostility to abusive bosses when the leader’s performance was high, and employees were even likely to think their career could be boosted by a successful – if abusive – boss. The findings suggest that employees may be reluctant to call a successful boss abusive – ...

UNC researchers identify potential treatment for Angelman syndrome

2024-07-08

CHAPEL HILL, N.C. – Angelman syndrome is a rare genetic disorder caused by mutations in the maternally-inherited UBE3A gene and characterized by poor muscle control, limited speech, epilepsy, and intellectual disabilities. Though there isn't a cure for the condition, new research at the UNC School of Medicine is setting the stage for one. Ben Philpot, PhD, the Kenan Distinguished Professor of Cell Biology and Physiology at the UNC School of Medicine and associate director of the UNC Neuroscience Center, and his lab have identified a small molecule that could be safe, non-invasively delivered, and capable of ...

Study: Weaker ocean circulation could enhance CO2 buildup in the atmosphere

2024-07-08

As climate change advances, the ocean’s overturning circulation is predicted to weaken substantially. With such a slowdown, scientists estimate the ocean will pull down less carbon dioxide from the atmosphere. However, a slower circulation should also dredge up less carbon from the deep ocean that would otherwise be released back into the atmosphere. On balance, the ocean should maintain its role in reducing carbon emissions from the atmosphere, if at a slower pace. However, a new study by an MIT researcher finds that scientists may have to rethink the relationship between the ocean’s circulation and its ...

Tirzepatide improves blood sugar control in children aged 10-17 years with type 2 diabetes inadequately controlled on existing therapies (SURPASS-PEDS trial)

Diet quality among children

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: